Concord Wealth Partners Iovance Biotherapeutics, Inc. Transaction History

Concord Wealth Partners

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 27, 2023	BUY	$5.62 - $10.0 $106 - $190	19 New	19 $0
Q2 2022 Aug 04, 2022	SELL	$6.38 - $18.33 $3,279 - $9,421	-514 Reduced 85.1%	90 $1,000
Q1 2022 Apr 20, 2022	SELL	$12.38 - $19.1 $5,112 - $7,888	-413 Reduced 40.61%	604 $10,000
Q4 2021 Jan 21, 2022	BUY	$16.55 - $27.63 $7,397 - $12,350	447 Added 78.42%	1,017 $19,000
Q3 2021 Nov 09, 2021	BUY	$20.35 - $26.63 $6,349 - $8,308	312 Added 120.93%	570 $14,000
Q2 2021 Jul 29, 2021	SELL	$16.33 - $33.07 $2,449 - $4,960	-150 Reduced 36.76%	258 $7,000
Q1 2021 May 13, 2021	BUY	$28.67 - $52.59 $10,579 - $19,405	369 Added 946.15%	408 $13,000
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $1,093 - $1,960	39 New	39 $2,000

319

243M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $923M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.